Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines

British Journal of Cancer

Volumn 79, Issue 2, 1999, Pages 293-299

  Kroning R ^a   Katz, D ^a   Lichtenstein, A K ^a   Nagami, G T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Carboplatin; Cisplatin; Nephrotoxicity; Renal tubule epithelial cell lines; Transport

Indexed keywords

CARBOPLATIN; CISPLATIN; PROTEIN BCL X;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG UPTAKE; EPITHELIUM CELL; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; TRANSGENE;

EID: 0032917760     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690047     Document Type: Article

References (30)

1. Binks SP and Dobrota M (1990) Kinetics and mechanics of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem Pharmacol 40: 1329-1336
2. Blachley JD and Hill JB (1981) Renal and electrolyte disturbances associated with cisplatin. Ann Int Med 95: 628-632
3. Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G and Gullans SR (1990) Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am J Physiol 258: F1181-F1187
4. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ and Trump BF (1982) Cis-diamminedichloroplatinum-induced acute renal failure in the rat. Kidney Int 21: 54-64
5. Colvin M (1993) Alkylating agents and platinum antitumor compounds. In Cancer Medicine, Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL and Weichselbaum RR (eds), pp. 733-754. Lea & Febiger: Philadelphia
6. Daley-Yates PT and McBrien DC (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33: 3063-3070
7. Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192-196
8. Fady C, Gardner A, Jacoby F, Briskin K, Tu Y, Schmid I and Lichtenstein AK (1995) Atypical apoptotic cell death induced in L929 targets by exposure to tumor necrosis factor. J Interferon Cytokine Res 15: 71-80
9. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E and Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39: 1362-1371
10. Guo JH (1992) Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients. Chung-Hua Chung Liu Tsa Chih Chinese J Oncol 14: 150-153
11. Hospers GAP, Mulder NH, de Jong B, de Ley L, Uges DRA, Fichtinger-Schepman AMJ, Scheper RJ and de Vries EGE (1988) Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 48: 6803-6807
12. Kaunitz JD, Cummins VP, Mishler D and Nagami GT (1993) Inhibition of gentamicin uptake into cultured mouse proximal tubule epithelial cells by L-lysine. J Clin Pharmacol 33: 63-69
13. Klaushofer K, Varga F, Glantschnig H, Fratzl-Zelman N, Czerwenka E, Leis HJ, Koller K and Peterlik M (1995) The regulatory role of thyroid hormones in bone cell growth and differentiation. J Nutrition 125 (suppl. 7): 1996S-2003S
14. Knox RJ, Freidlos F, Lydall DA and Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine (1,1-cyclobutanedicarboxylate) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972-1979
15. Leibbrandt MEI, Wolfgang GHI, Metz AL, Ozobia AA and Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48: 761-770
16. Lieberthal W, Triaca V and Levine J (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270: F700-F708
17. Loehrer PJ and Einhorn LH (1984) Cisplatin. Ann Int Med 100: 704-713
18. Mann SC, Andrews PA and Howell SB (1990) Short-term cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 35: 236-240
19. Mellish KJ, Kelland LR and Harrap KR (1993) In Vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68: 240-250
20. Micetich KC, Barnes D and Erickson LL (1985) A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino) (1,1-cyclobutanedicarboxylate)-platinum (II) and cis-diamminedichloroplatinum (II) on L1210 cells. Cancer Res 45: 4043-1047
21. Minn AJ, Rudin CM, Boise L Thompson CB (1995) Expression of BCL-X-L can confer a multidrug resistance phenotype. Blood 86: 1903-1910
22. Mistry P, Lee C and McBrien DC (1989) Intracellular metabolites of cisplatin in the rat kidney. Cancer Chemother Pharmacol 24: 73-79
23. Miyashita T and Reed JC (1992) BCL-2 gene transfer increases relative resistance of S49.1 and WEHI 7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and chemotherapeutic drugs. Cancer Res 52: 5407-5411
24. Nagami GT, Warech EM and Mischler DR (1990) Cells derived from S1, S2 and S3 proximal tubule segments of a transgenic mouse. J Am Soc Nephrol 1: 656
25. Nagami GT, Warech EM and Mischler DR (1991) Effect of angiotensin II on ammonia production by mouse S1 and S3 proximal tubule cell lines. J Am Soc Nephrol 2: 707
26. Nagami GT, Warech EM and Mischler DR (1992) Ammonia production and transport by cultured proximal tubule cells grown on permeable supports. J Am Soc Nephrol 3: 783
27. Palmiter RD, Chen HY, Messing A and Brinster RL (1985) SV 40 enhancer and large-T antigen are instrumental in development of choroid plexus tumors in transgenic mice. Nature 316: 457-460
28. Parti R and Wolf W (1990) Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin. Cancer Chemother Pharmacol 26: 188-192
29. Schurig JE, Rose WC, Catino JJ, Gaver RC, Long BH, Madissoo H and Canetta R (1990) The Pharmacologic Characteristics of Carboplatin: Preclinical Experience. In Carboplatin (JM-8), Current Perspectives and Future Directions, Bunn PA, Canetta R, Ozols RF and Roseneweig M (eds), pp. 3-17. WB Saunders: Philadelphia
30. Simonian PC, Grillot DAM and Nunez G (1997) BCL-2 and BCL-XL can differentially block chemotherapy induced cell death. Blood 90: 1208-1216